Afoxolaner

Afoxolaner (CAS 1093861-60-9) is a systemic isoxazoline ectoparasiticide developed for veterinary use, primarily in dogs. It acts by inhibiting GABA- and glutamate-gated chloride channels, leading to rapid paralysis and death of fleas and ticks. This compound is supplied as a white to off-white crystalline powder with ≥98% HPLC purity, suitable for oral solid dosage forms.

Synonyms: 1-Naphthalenecarboxamide, 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-(2,2,2-trifluoroethyl)amino]ethyl]-, (5S)-; Afoxolaner (USAN); NexGard® active ingredient; 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide

Applications

• Veterinary formulations for flea and tick control in dogs
• Combination products with other parasiticides (e.g., milbemycin oxime)
• R&D and scale-up for oral tablet development

Quality & Documentation

Every batch is tested for assay (HPLC ≥98%), loss on drying (≤0.5%), and heavy metals (≤10 ppm). Full COA, MSDS, and TDS are provided per batch. Stability data and impurity profiles are available on request for qualification.

Packaging & Supply

Standard packaging: 1 kg, 5 kg, 25 kg; bulk and custom packing available. In-stock items ship within 3-5 days; MOQ from 1 kg. For pricing, samples, and bulk orders, contact our sales team.

Request For Quote

• Our Address: 280 Main Street, Xian, Shaanxi, China
• LyvBio Co., Ltd. — Email: info@lyvbio.com